Citation | Maini pioneered the use of anti-TNF monoclonal antibodies for the treatment of rheumatoid arthritis, thereby establishing the concept of using biological targeted therapies in autoimmune diseases. These seminal advances were based upon a series of elegant experiments using animal models and human tissues, as well as clinical studies. A notable advance was the demonstration that the effect and durability of anti-TNF therapy was markedly enhanced by co-therapy with methotrexate. His studies have established anti-TNF as a safe, highly effective, commercially successful therapy which protects joints and restores quality of life and which, in consequence, has revolutionised rheumatology clinical practice worldwide. |